All In Biotech

Drug Trial Radar · NCT05347849

Single Ascending Dose Study With BPL-003 in Healthy Subjects

A Two-part Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal BPL-003 (5-Methoxy-N,N-dimethyltryptamine Benzoate) in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

62

Actual

Start

Feb 14, 2022

Primary completion

Jan 19, 2024

Study completion Jan 19, 2024

Sponsor

Lead sponsor
Beckley Psytech LimitedIndustry
Sponsor type
Industry
First posted
Apr 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 25 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will evaluate safety, tolerability and PK profile of BPL-003 in healthy subjects

Conditions

  • Pharmacokinetics in Healthy Adults

Interventions

  • BPL-003Drug

    A single dose of BPL-003 will be administered intranasally

  • PlaceboOther

    A single dose of placebo will be administered intranasally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with treatment emergent AEs (TEAES)Time frame: From screening through to the follow up visit, up to 65 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hammersmith Medicines Research

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.